frederic Iseni

Dr. frederic Iseni

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2022 in Nature Microbiology
Verified
Journal Article
Closed access
PDF file
GFGaëlle Frenois-Veyrat
Gaëlle Frenois-Veyrat
FGFranck Gallardo
Franck Gallardo
OGOlivier Gorgé
Olivier Gorgé
EMElie Marcheteau
Elie Marcheteau
OFOlivier Ferraris
Olivier Ferraris
JTJean-Nicolas Tournier
Jean-Nicolas Tournier

13 November 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
NTNicolas Tarbouriech
Nicolas Tarbouriech
CDCorinne Ducournau
Corinne Ducournau
SHStephanie Hutin
Stephanie Hutin
PMPhilippe J. Mas
Philippe J. Mas
PMPetr Man
Petr Man
FIfrederic Iseni
frederic Iseni
Vaccinia virus (VACV), the prototype member of thePoxviridae, replicates in the cytoplasm of an infected cell. The catalytic subunit of the DNA polymerase E9 binds the heterodimeric processivity factor A20/D4 to form the functional polymerase holoenzyme. Here we present the crystal structure of full-length E9 at 2.7 Å resolution that permits identification of important poxvirus-specific structural insertions. One insertion in the palm domain interacts with C-terminal residues of A20 and thus serves as the processivity factor-binding site. This is in strong contrast to all other family B polymerases that bind their co-factors at the C terminus of the thumb domain. The VACV E9 structure also permits rationalization of polymerase inhibitor resistance mutations when compared with the closely related eukaryotic polymerase delta–DNA complex.

6 March 2014 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
CCCéline Contesto-Richefeu
Céline Contesto-Richefeu
NTNicolas Tarbouriech
Nicolas Tarbouriech
XBXavier Brazzolotto
Xavier Brazzolotto
SBStephane Betzi
Stephane Betzi
XMXavier Morelli
Xavier Morelli
FIfrederic Iseni
frederic Iseni
Vaccinia virus polymerase holoenzyme is composed of the DNA polymerase E9, the uracil-DNA glycosylase D4 and A20, a protein with no known enzymatic activity. The D4/A20 heterodimer is the DNA polymerase co-factor whose function is essential for processive DNA synthesis. Genetic and biochemical data have established that residues located in the N-terminus of A20 are critical for binding to D4. However, no information regarding the residues of D4 involved in A20 binding is yet available. We expressed and purified the complex formed by D4 and the first 50 amino acids of A20 (D4/A201–50). We showed that whereas D4 forms homodimers in solution when expressed alone, D4/A201–50 clearly behaves as a heterodimer. The crystal structure of D4/A201–50 solved at 1.85 Å resolution reveals that the D4/A20 interface (including residues 167 to 180 and 191 to 206 of D4) partially overlaps the previously described D4/D4 dimer interface. A201–50 binding to D4 is mediated by an α-helical domain with important leucine residues located at the very N-terminal end of A20 and a second stretch of residues containing Trp43 involved in stacking interactions with Arg167 and Pro173 of D4. Point mutations of the latter residues disturb D4/A201–50 formation and reduce significantly thermal stability of the complex. Interestingly, small molecule docking with anti-poxvirus inhibitors selected to interfere with D4/A20 binding could reproduce several key features of the D4/A201–50 interaction. Finally, we propose a model of D4/A201–50 in complex with DNA and discuss a number of mutants described in the literature, which affect DNA synthesis. Overall, our data give new insights into the assembly of the poxvirus DNA polymerase cofactor and may be useful for the design and rational improvement of antivirals targeting the D4/A20 interface. Vaccinia virus is the prototype of the orthopoxvirus genus which includes other pathogens infecting humans and variola virus which was eradicated in the late 70's. Vaccinia virus DNA synthesis relies on three proteins: these are E9, the DNA polymerase bound to its heterodimeric cofactor D4/A20. To date, the molecular mechanism involved in poxvirus DNA replication remains poorly understood. Here, we present the high-resolution crystal structure of a complex formed by D4 and the first 50 residues of A20 (A201–50) that are necessary and sufficient for binding. The structure of D4/A201–50 reveals the contact surface engaged in the D4/A20 interaction in great detail. Interestingly, we could show that known small molecule inhibitors of vaccinia virus DNA synthesis selected for their ability to interfere with the D4/A20 interface could be docked onto the D4 surface where they mimic several aspects of the interacting A20 molecule. Finally, we present a model of D4/A20 in complex with DNA that allows us to discuss the role of mutations affecting the D4/A20 cofactor. Altogether, our structure gives new insights into the assembly of the vaccinia virus DNA polymerase cofactor and will be useful for the design of new antiviral compounds targeting the D4/A20 interaction.

1 July 2015 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
WBWim Pascal BURMEISTER
Wim Pascal BURMEISTER
NTNicolas Tarbouriech
Nicolas Tarbouriech
Pascal FenderPascal Fender
Pascal Fender
CCCéline Contesto-Richefeu
Céline Contesto-Richefeu
CPChristophe N. Peyrefitte
Christophe N. Peyrefitte
FIfrederic Iseni
frederic Iseni
Vaccinia virus polymerase holoenzyme is composed of the DNA polymerase catalytic subunit E9 associated with its heterodimeric co-factor A20/D4 required for processive genome synthesis. While A20 has no known enzymatic activity, D4 is an active uracil-DNA glycosylase (UNG) . The presence of a repair enzyme as a component of the viral replication machinery suggest that, for poxviruses, DNA synthesis and base excision repair is coupled. We present the 2.7Å crystal structure of the complex formed by D4 and the first 50 amino acids of A20 (D4/A201 50) bound to a 10-mer DNA duplex containing an abasic site resulting from the cleavage of a uracil base. Comparison of the viral complex with its human counterpart revealed major divergences in the contacts between protein and DNA and in the enzyme orientation on the DNA. However, the conformation of the dsDNA within both structures is very similar suggesting a dominant role of the DNA conformation for UNG function. In contrast to human UNG, D4 appears rigid and we do not observe a conformational change upon DNA binding. We also studied the interaction of D4/A201-50 with different DNA oligomers by surface plasmon resonance. D4 binds weakly to non-specific DNA and to uracil containing substrates but binds abasic sites with a Kd < 1.4 μM. This second DNA complex structure of a family I UNG gives new insight into the role of D4 as a co-factor of vaccinia virus DNA polymerase and allows a better understanding of the structural determinants required for UNG action.

1 June 2021 in Journal of Molecular Biology
Verified
Journal Article
Open access
BBBeate Bersch
Beate Bersch
NTNicolas Tarbouriech
Nicolas Tarbouriech
WBWim Pascal BURMEISTER
Wim Pascal BURMEISTER
FIfrederic Iseni
frederic Iseni
Poxviruses are enveloped viruses with a linear, double-stranded DNA genome. Viral DNA synthesis is achieved by a functional DNA polymerase holoenzyme composed of three essential proteins. For vaccinia virus (VACV) these are E9, the catalytic subunit, a family B DNA polymerase, and the heterodimeric processivity factor formed by D4 and A20. The A20 protein links D4 to the catalytic subunit. High-resolution structures have been obtained for the VACV D4 protein in complex with an N-terminal fragment of A20 as well as for E9. In addition, biochemical studies provided evidence that a poxvirus-specific insertion (insert 3) in E9 interacts with the C-terminal residues of A20. Here, we provide solution structures of two different VACV A20 C-terminal constructs containing residues 304-426, fused at their C-terminus to either a BAP (Biotin Acceptor Peptide)-tag or a short peptide containing the helix of E9 insert 3. Together with results from titration studies, these structures shed light on the molecular interface between the catalytic subunit and the processivity factor component A20. The interface comprises hydrophobic residues conserved within the Chordopoxvirinae subfamily. Finally, we constructed a HADDOCK model of the VACV A20304-426-E9 complex, which is in excellent accordance with previous experimental data.

18 July 2022 in Viruses
Verified
Journal Article
Open access
PDF file
LBLaetitia Boutin
Laetitia Boutin
EMEstelle Mosca
Estelle Mosca
FIfrederic Iseni
frederic Iseni
The vaccinia virus (VACV) was previously used as a vaccine for smallpox eradication. Nowadays, recombinant VACVs are developed as vaccine platforms for infectious disease prevention and cancer treatment. The conventional method for genome editing of the VACV is based on homologous recombination, which is poorly efficient. Recently, the use of CRISPR/Cas9 technology was shown to greatly improve the speed and efficiency of the production of recombinant VACV expressing a heterologous gene. However, the ability to rapidly recover viruses bearing single nucleotide substitutions is still challenging. Notwithstanding, ongoing studies on the VACV and its interaction with the host cell could benefit from viral gene targeted mutagenesis. Here, we present a modified version of the CRISPR/Cas9 system for the rapid selection of mutant VACV carrying point mutations. For this purpose, we introduced a silent mutation into the donor gene (which will replace the wildtype gene) that serves a double function: it is located in the PAM (NGG) sequence, which is essential for Cas9 cleavage, and it alters a restriction site. This silent mutation, once introduced into the VACV genome, allows for rapid selection and screening of mutant viruses carrying a mutation of interest in the targeted gene. As a proof of concept, we produced several recombinant VACVs, with mutations in the E9L gene, upon which, phenotypic analysis was performed.